Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors

NCT02592785 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Bayer